MRNA catalyst calendar

Moderna, Inc.

Upcoming catalysts
28
Cash runway
24.5 months
Cash & investments
$5138M
Phase 3 programs
23

Moderna, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on October 16, 2026, a projected date rather than a confirmed one. There are 28 upcoming events on record.

Cash runway is approximately 24.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 86 concluded trials, 88% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 16, 2026 est. Next quarterly earnings (projected) Earnings —
October 29, 2026 Q3 2026 Earnings Earnings —
November 10, 2026 est. mRNA-4359 — Phase 2 Cancer Antigen Therapy Readout Trial Readout Phase 2
November 30, 2026 A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) Trial Milestone Phase 1/Phase 2
December 10, 2026 est. Propionic Acidemia (mRNA-3927) — Registrational Data Trial Readout Registrational
December 16, 2026 A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants Trial Milestone Phase 1
December 31, 2026 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations Trial Milestone Phase 4
January 9, 2027 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations Trial Milestone Phase 4
January 28, 2027 A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults Trial Milestone Phase 3
February 15, 2027 A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis Trial Milestone Phase 3
March 6, 2027 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. Trial Milestone Phase 2
May 15, 2027 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age Trial Milestone Phase 1
June 16, 2027 A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) Trial Milestone Phase 4
July 20, 2027 A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults Trial Milestone Phase 1
August 3, 2027 A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors Trial Milestone Phase 1
August 31, 2027 Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia Trial Milestone Phase 1/Phase 2
September 30, 2027 A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants Trial Milestone Phase 1
November 21, 2027 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors Trial Milestone Phase 1
December 7, 2027 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children Trial Milestone Phase 1
November 9, 2028 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) Trial Milestone Phase 2
January 8, 2029 A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years Trial Milestone Phase 2
August 30, 2029 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age Trial Milestone Phase 2
August 31, 2029 A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Trial Milestone Phase 1
December 4, 2029 A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study Trial Milestone Phase 1/Phase 2
June 17, 2030 A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
February 18, 2032 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
November 21, 2032 An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Trial Milestone Phase 2
April 2, 2034 An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 Trial Milestone Phase 1/Phase 2

Track MRNA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MRNA in the tracker

Recent history

DateEventTypePhase
October 13, 2026 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants Trial Milestone Phase 1
October 5, 2026 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults Trial Milestone Phase 1/Phase 2
September 30, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 22, 2026 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age Trial Milestone Phase 1/Phase 2
September 1, 2026 8-K filed: Material agreement, Other event Corporate —
August 19, 2026 Intismeran Autogene — Phase 3 INTerpath-001 (Melanoma) Trial Readout Phase 3
August 5, 2026 mFLUSIVA (mRNA-1010) — FDA PDUFA Decision Regulatory BLA
July 31, 2026 Quarterly results filed (8-K) Earnings —
July 31, 2026 Q2 2026 Earnings + Norovirus Interim Analysis Earnings Phase 3 interim
July 24, 2026 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults Trial Milestone Phase 3
July 8, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 18, 2026 mFLUSIVA (mRNA-1010) — FDA Advisory Committee Vote Regulatory BLA review
June 16, 2026 A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations Trial Milestone Phase 4
June 1, 2026 Intismeran + KEYTRUDA — 5-Year Phase 2b Melanoma Data Conference Phase 2b
May 25, 2026 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers Trial Milestone Phase 2
May 12, 2026 A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age Trial Milestone Phase 1/Phase 2
May 1, 2026 Quarterly results filed (8-K) Earnings —
April 1, 2026 A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Trial Milestone Phase 1/Phase 2
March 27, 2026 A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age Trial Milestone Phase 3
March 5, 2026 8-K filed: Material agreement Corporate —
February 27, 2026 A Study of Modified mRNA Vaccines in Healthy Adults Trial Milestone Phase 1
February 13, 2026 Quarterly results filed (8-K) Earnings —
February 11, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 19, 2026 A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine Trial Milestone Phase 2
January 12, 2026 Quarterly results filed (8-K) Earnings —
January 5, 2026 8-K filed: Reg FD disclosure Filing —
December 31, 2025 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age Trial Milestone Phase 1
November 24, 2025 8-K filed: Material agreement Corporate —
November 20, 2025 8-K filed: Reg FD disclosure Filing —
November 17, 2025 Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.